Journals / Türk Kardiyoloji Derneği Arşivi / 2010 / Cilt: 38 - Sayı: 8

Adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetics and secondary prevention patients: The role of education and knowledge

Tip 2 diyabetiklerde ve ikincil koruma hastalarında statin kullanımına uyum ve LDL-kolesterol hedefine ulaşma düzeyleri: Eğitim ve bilgi düzeyinin rolü

Pages
544–550
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We evaluated adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetic and secondary prevention patients.Study design: A total of 194 patients (131 men, 63 women; mean age 57±11 years) who had been on statin therapy for at least a year for a target LDL cholesterol level of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Lipid levels of most patients receiving antilipidemic therapy are not under control as proposed by the guidelines.
📊
Key Findings & Data:Objectives: Lipid levels of most patients receiving antilipidemic therapy are not under control as proposed by the guidelines.
💡
Conclusion & Impact:We evaluated adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetic and secondary prevention patients.Study design: A total of 194 patients (131 men, 63 women; mean age 57±11 years) who had been on statin therapy for at least a year for a target LDL cholesterol level of
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Lipid levels of most patients receiving antilipidemic therapy are not under control as proposed by the guidelines. We evaluated adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetic and secondary prevention patients.Study design: A total of 194 patients (131 men, 63 women; mean age 57±11 years) who had been on statin therapy for at least a year for a target LDL cholesterol level of

Özet

Amaç: Lipit düşürücü tedavi gören hastaların büyük kısmında lipit değerleri kılavuzlara uygun şekilde kontrol altında değildir. Çalışmamızda tip 2 diyabetik ve ikincil koruma hastalarında statin kullanımına uyum ve LDL-kolesterol hedefine ulaşma düzeyleri değerlendirildi.Çalışma planı: Hedef LDL-kolesterol değeri 100 mgr/dl altı olan ve en az bir yıldır statin tedavisi gören 194 hastaya (131 erkek, 63 kadın; ort. yaş 57±11) iki bölümden oluşan bir anket uygulandı. Birinci bölümde hastaların demografik ve klinik özellikleri, hiperlipidemi süresi, diyetisyen ile görüşme durumu, risk faktörleri ve varsa antilipidemik ilacı kesme nedenleri irdelendi. İkinci bölüm ise hastaların hiperkolesterolemi konusunda bilgi düzeylerini ölçen 23 sorudan (toplam puan 30) oluşmaktaydı.Bulgular: Çalışma grubunun %31.4’ü (n=61) birincil korumadaki diyabetik hastalar, %68.6’sı (n=133) ikincil koruma hastalarıydı. LDL-kolesterol ortalaması 122.6±28.7 mgr/dl ve hedef değere ulaşma oranı %23.7 (n=46) bulundu. Diyabetik hastalarda hedef değere ulaşma ikincil koruma hastalarından anlamlı derecede düşüktü (%6.6 ve %31.6, p

🔖

Cite This Article

İNANÇ, T., ARSLAN, E., ÖZÇELİK, F., ŞAHİN, İ., ÖZMEN, N., CEBECİ, B. S., KARDEŞOĞLU, E., APARCI, M., IŞILAK, Z., YİĞİNER, Ö., UZ, Ö. (2022). Adherence to statin therapy and LDL cholesterol goal attainment in type 2 diabetics and secondary prevention patients: The role of education and knowledge. Türk Kardiyoloji Derneği Arşivi, Cilt: 38 - Sayı: 8, 544–550. https://ajindex.com/articles/633305

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001;285:2486-97
  2. Management of dyslipidemia in adults with diabetes. American Diabetes Association. Diabetes Care 1998; 21:179-82
  3. Hermans MP, Van Mieghem W, Vandenhoven G, Vissers E. Centralized Pan European survey on the undertreatment of hypercholesterolaemia (CEPHEUS). Acta Cardiol 2009;64:177-85
  4. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
  5. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D; EUROASPIRE II Study Group. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008;197:710-7
  6. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37
  7. Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm 2007; 13:652-63
  8. Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9
  9. Ferrières J, Gousse ET, Fabry C, Hermans MP; French CEPHEUS Investigators. Assessment of lipid-lowering treatment in France-the CEPHEUS study. Arch Cardiovasc Dis 2008;101:557-63
  10. Kültürsay H. Results of the rosuvastatin studies in Turkey. [Article in Turkish] Türk Kardiyol Dern Arş 2007;35(Suppl 1):24-30
  11. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
  12. Pyörälä K, Lehto S, De Bacquer D, De Sutter J, Sans S, Keil U, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASP